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Recently, we have shown that the CCL5/CCR5 axis is active in patients affected by an aggressive basal subtype of breast
cancer. Using preclinical models, we have demonstrated that CCR5 promotes breast cancer invasiveness and metastatic
potential, while CCR5 inhibition abrogates them. Thus, CCR5 antagonists may constitute an alternative therapeutic
approach for patients affected by metastatic basal breast cancer.

We have recently analyzed the expression
of the chemokine CCL5 and its receptors
in human breast cancer samples as well as
in the normal breast epithelium.1 We found
that CCL5/CCR5 signaling is preferentially active in basal and ERBB2+ disease
subtypes. Analyzing a combined microarray database including 2,254 samples from
27 independent studies,2 we demonstrated
that 58% or more patients affected by the
basal and ERBB2+ subtype of breast cancer
significantly overexpress both CCL5 and
CCR5. In contrast, when a similar analysis was performed in non-neoplastic breast
samples, no correlation between CCL5 and
CCR5 expression levels was found, indicating that CCL5/CCR5 signaling may be
preferentially activated during the development of specific breast cancer subtypes.
In line with this notion, the invasiveness
of human MCF-10A breast cancer cells
transduced with Neu-T, H-RAS or c-SRC
oncogenes increased in response to CCL5,
suggesting that CCL5/CCR5 signaling is
activated by oncogenic events to promote
an aggressive phenotype.
Patients affected by basal breast carcinomas are at increased risk of metastasis and exhibit poor survival rates.3,4
Thus, we evaluated the importance of
the CCL5/CCR5 axis in invasion and
metastasis. By using human breast cancer cell lines exhibiting a basal phenotype

and molecular signature, we demonstrated that the increased expression of
CCR5 we had observed in tissue microarray might be caused by the existence
of a CCR5 + cell population. Phenotypic
analyses demonstrated that a small fraction of cells within breast cancer cell lines
express CCR5 and functional analyses
showed that such CCR5 + cells respond
to CCL5. Furthermore, basal breast cancer cells expressing CCR5 display an
increased invasiveness and metastatic
potential. Metastatic tumors generated by
the intravenous injection of breast cancer
MDA-MB-231 cells transduced with a
lentiviral vector coding for luciferase fused
to an enhanced variant of the green-fluorescent protein (Luc2-eGFP) displayed
an 8-fold increase in the proportion of
CCR5 + cells as compared with the same
cell line maintained in vitro. This indicates either that the invasive population is
enriched in CCR5 + cells or that the microenviroment at metastatic sites promotes a
CCR5 + phenotype. In an additional series
of experiments, we showed that CCR5 +
cells isolated from basal breast cancer
cell lines are approximately 40-fold more
invasive in vitro than their CCR5- counterparts, indicating that CCR5 expression
correlates with a pro-invasive phenotype.
The importance of CCR5 in HIV
infection led to the development of

drugs that specifically target this receptor. CCR5 antagonists, which were originally developed to prevent the interaction
between CCR5 and the gp120 glycoprotein of HIV-1, can efficiently block CCR5
activity at nanomolar concentrations.5,6
We therefore examined the possibility that
CCR5 inhibition may reduce the invasive
and metastatic potential of breast cancer
cells. The CCR5 antagonists Maraviroc
and Vicriviroc (both employed at a concentration of 100 nM) impaired CCL5stimulated cytoplasmic calcium waves and
reduced the invasiveness of basal breast
cancer cells. We also evaluated Maraviroc
effects in vivo, using a mouse model of
metastatic breast cancer. The intravenous injection of Luc2-eGFP-expressing
MDA-MB-231 breast cancer cells indeed
generates pulmonary metastasis that can
be easily followed by bioluminescence
imaging. In this setting, the administration of Maraviroc at the clinically relevant
dose of 8 mg/kg (twice daily) efficiently
reduced pulmonary tumor burden
(Fig. 1). Histological analyses performed
on animals treated with Maraviroc for five
weeks confirmed a significant reduction
of both the number and the size of pulmonary metastases (Fig. 1). Only 50% of
Maraviroc-treated mice exhibited detectable neoplastic lesions and mean tumor
size was reduced by > 65% as compared
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Figure 1. The CCR5 antagonist Maraviroc inhibits lung metastases in vivo. MDA-MB-231 cells expressing luciferase fused to an enhanced variant of the
green-fluorescent protein (Luc2-eGFP) were injected into the tail vein of NOD/SCID mice and the bioluminescent signal was quantified weekly in vivo.
Representative images of mice receiving vehicle or 8 mg/Kg Maraviroc (every 12 h) are shown in (A) Quantitative data on bioluminescence imaging
(means ± SEM, n = 6) are reported in panel (B) (control mice = red line; treated mice = blue line). Statistical comparisons (*p = 0.048) were by means
of Student’s t-tests coupled to Welch’s correction for heterogeneous variances. (C) The presence of pulmonary tumors and the differences between
experimental groups were corroborated by ex vivo imaging (left panels) and India ink staining (right panels).

with vehicle-treated mice. These results
demonstrate (1) that basal breast cancer cells are sensitive to pharmacological
CCR5 inhibition, and (2) that the proinvasive and pro-metastatic activities of
CCR5 can be abrogated by using specific
antagonists.
CCR5 has also been shown to alter the
proliferation of luminal breast cancer7,8
and prostate cancer cell lines.9 However,
the impact of CCR5 on the proliferation of basal cancer cells is controversial.
The results obtained with our model of

e23660-2

metastatic breast cancer did not allow us
to understand whether CCR5 influences
cell proliferation or tissue colonization.
We therefore analyzed the role of CCR5
on tumor cell proliferation by three different strategies. We observed that (1)
Maraviroc as well as Vicriviroc do not
affect the viability and proliferative potential of MDA-MB-231 cells in vitro; (2)
CCR5 overexpressing cells display the
same proliferation rate as cells transfected
with an empty vector; and (3) the administration of Maraviroc does not alter the
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growth of pre-established pulmonary
metastases in vivo. Taken together, these
results indicate that CCR5 activation does
not promote the proliferation of basal
breast cancer cells and that the anti-metastatic effect of CCR5 antagonists does not
stem from effects on tumor growth.
To further clarify the mechanisms by
which CCR5 promotes metastasis, we
evaluated the effects of Maraviroc on the
homing of breast cancer cells to the lungs.
Of note, Maraviroc reduced the number of
cancer cells that could be detected in the
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lungs of mice 24 h after intravenous injection by 40%. Our results are in agreement
with previous findings demonstrating that
the CCL5/CCR5 signaling axis plays a
crucial role in the metastatic cascade as it
is involved in cancer cell extravasation.10
Blocking the homing of cancer cells to
metastatic sites is a highly desirable feature
for a bona fide anti-metastatic drug.
Our recent paper1 demonstrates for the
first time that the expression of CCR5
and CCL5 correlates with a metastatic
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